Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Smeaton, Laura M.; Kileel, Emma M.; Grinsztejn, Beatriz; Gardner, Edward M.; Starr, Kate; Murry, Melissa L.; Desvigne-Nickens, Patrice; Alston-Smith, Beverly; Waclawiw, Myron A.; Cooper-Arnold, Katharine; Madruga, José V.; Sangle, Shashi; Fitch, Kathleen V.; Zanni, Markella V.; Douglas, Pamela S.; Ribaudo, Heather J.; Grinspoon, Steven K.; Klingman, Karin L..
Artículo en Inglés | ARCA | ID: arc-43098

Documentos relacionados

  1. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
  2. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
  3. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
  4. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
  5. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.
  6. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.
  7. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
  8. Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.
  9. An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.
  10. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).